Dual anti platelets ticaglor and aspirin for inferior stemi
Reading File
Finding Sources
Finding Sources
Searching PubMed
ticagrelor aspirin STEMI dual antiplatelet
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
I have comprehensive information from multiple authoritative sources. Here is a detailed, well-structured answer:
Dual Antiplatelet Therapy (DAPT): Ticagrelor + Aspirin in Inferior STEMI
Rationale for DAPT
Aspirin alone exerts only modest platelet inhibition via irreversible COX-1 inhibition, reducing thromboxane A2 synthesis. Adding a P2Y12 receptor antagonist — forming DAPT — provides more potent, complementary antiplatelet action by blocking ADP-mediated platelet activation. This is critical in STEMI because the culprit plaque rupture triggers intense platelet aggregation and thrombus formation regardless of the infarct territory (inferior, anterior, lateral).
Inferior STEMI does not change the DAPT regimen — the evidence base and guideline recommendations apply uniformly to all STEMI presentations.
Ticagrelor: Mechanism & Pharmacology
Ticagrelor is a reversible, direct-acting P2Y12 receptor antagonist (cyclopentyl-triazolo-pyrimidine class) — it does not require hepatic activation (unlike clopidogrel/prasugrel). Key pharmacokinetic features:
| Property | Detail |
|---|---|
| Onset of action | Rapid; peak plasma concentration ~2.5 hours |
| Binding | Reversible (allosteric) |
| Duration of effect | Prolonged — platelet function recovers over ~3–5 days after last dose |
| Dosing (STEMI) | 180 mg loading dose, then 90 mg twice daily |
| Hold before surgery | 5 days pre-operatively |
Because it doesn't require CYP conversion, there is no genetic variability in response (unlike clopidogrel's CYP2C19 poor-metabolizer issue).
Key Evidence: The PLATO Trial
The pivotal trial is PLATO (Platelet Inhibition and Patient Outcomes):
- n = 18,624 patients with ACS; 38% had STEMI
- Ticagrelor 180 mg load → 90 mg BID vs. clopidogrel 300–600 mg load → 75 mg daily
- ~2/3 underwent PCI
Results at 12 months:
- 16% relative reduction in composite of vascular death, MI, or stroke with ticagrelor (9.8% vs 11.7%)
- CV death alone reduced (4.0% vs 5.1%; HR 0.79)
- Major bleeding unrelated to CABG: slightly higher with ticagrelor (4.5% vs 3.8%; P = 0.03)
- Fatal intracranial bleeding: higher with ticagrelor
- Stroke in STEMI subgroup: slightly higher with ticagrelor (1.7% vs 1.0%; P = 0.02) — a signal requiring attention
— Fuster and Hurst's The Heart, 15th Ed., p. 610
Dosing Regimen
| Drug | Loading Dose | Maintenance Dose | Duration |
|---|---|---|---|
| Aspirin | 162–325 mg (non-enteric-coated, chewed) | 75–100 mg daily | Indefinitely |
| Ticagrelor | 180 mg PO | 90 mg PO twice daily | 12 months |
- Aspirin should be non-enteric-coated in the acute setting to ensure rapid absorption
- IV aspirin 150 mg is an alternative for those unable to swallow (European guidelines)
- DAPT duration: 12 months is the standard recommendation for all STEMI patients regardless of revascularization strategy, absent high bleeding risk
"Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist (clopidogrel, prasugrel, or ticagrelor) is recommended for 12 months after a STEMI, in the absence of high bleeding risk or the occurrence of bleeding complications."
— Harrison's Principles of Internal Medicine, 22nd Ed., p. 2169
Ticagrelor vs. Alternatives in STEMI
| Agent | Benefit | Key Limitation |
|---|---|---|
| Clopidogrel | Only agent with fibrinolytic data; well-studied; cheaper | CYP2C19 variability; slower onset; less potent |
| Prasugrel | Greater anti-ischemic effect vs clopidogrel (TRITON-TIMI 38) | Higher bleeding; contraindicated in prior stroke/TIA; caution ≥75 yr or <60 kg |
| Ticagrelor | Reduced CV mortality vs clopidogrel (PLATO); no genetic variability | Twice-daily dosing; dyspnea (adenosine-mediated, ~15%); slightly higher intracranial bleeding |
| Cangrelor | IV, immediate onset; useful if unable to take oral meds or urgent CABG | IV only; short half-life (4–6 min); role still being defined |
Important: Ticagrelor and prasugrel are NOT recommended when fibrinolytic therapy is used — clopidogrel remains the only P2Y12 inhibitor indicated in the pharmaco-invasive strategy.
Timing in Inferior STEMI with Primary PCI
- Ticagrelor 180 mg loading dose should be given as early as possible — ideally at first medical contact / in the ED, before the patient reaches the cath lab
- Note: Despite rapid absorption, >30% of STEMI patients receiving a ticagrelor loading dose may show high residual platelet reactivity for up to 2 hours post-ingestion — likely due to delayed gastric emptying in the acute setting. Some centers bridge with IV cangrelor in this window
DAPT De-escalation and Duration Adjustments
Shortening DAPT (6 months)
- The DAPT-STEMI trial (n = 870) showed 6-month DAPT was non-inferior to 12 months in selected low-risk patients — but results must be interpreted cautiously (observed event rates far lower than projected)
- A larger ACS trial showed 6-month DAPT → higher MI rates vs. longer duration (1.8% vs 0.8%; P = 0.02)
- Current guidance: do not discontinue P2Y12 inhibition before 6 months post-STEMI
Aspirin-free strategy ("ticagrelor monotherapy")
Emerging data supports 1–3 months DAPT → ticagrelor alone:
- GLOBAL LEADERS (n = 15,968): 1 month DAPT → ticagrelor monotherapy reduced major bleeding by 48% vs standard DAPT (no difference in death/Q-wave MI)
- TICO trial: 3 months DAPT → ticagrelor monotherapy showed reduced MACE + bleeding vs 12-month DAPT
- Individual patient data meta-analysis (Ann Intern Med 2025, PMID 39961108): De-escalation to ticagrelor monotherapy associated with reduced bleeding without increase in ischemic events
This aspirin-dropping strategy is supported by pharmacodynamic data showing aspirin adds minimal incremental inhibition when ticagrelor is present at therapeutic levels.
Extended DAPT (>12 months)
- In PEGASUS-TIMI 54 (~53% had prior STEMI): aspirin + ticagrelor 60 mg BID for up to 3 years after MI reduced MACE (absolute risk reduction ~1%) at the cost of more bleeding
- Suitable only for high-ischemic/low-bleeding-risk patients beyond 1 year
Contraindications & Special Situations
| Situation | Recommendation |
|---|---|
| Prior intracranial hemorrhage | Ticagrelor contraindicated |
| Active pathological bleeding | Contraindicated |
| Severe hepatic impairment | Avoid ticagrelor |
| Planned CABG | Hold ticagrelor 5 days before surgery |
| Patient on oral anticoagulant (e.g., AF + STEMI) | Triple therapy: minimize duration; prefer clopidogrel over ticagrelor to reduce bleeding in combination |
| Age ≥75 years | Ticagrelor still preferred over prasugrel; weigh bleeding risk |
| Fibrinolysis given | Use clopidogrel, NOT ticagrelor |
Unique ticagrelor side effect — Dyspnea: Adenosine-mediated, non-bronchospastic; usually self-limiting. Occurs in ~15% — do not discontinue for this alone unless severe.
Summary
In inferior STEMI managed with primary PCI:
- Aspirin 162–325 mg (chewed, non-enteric) + Ticagrelor 180 mg loading dose as early as possible
- Continue aspirin 75–100 mg daily + ticagrelor 90 mg BID for 12 months
- Ticagrelor is preferred over clopidogrel (higher efficacy, no CYP variability) and over prasugrel (lower bleeding risk, suitable for older/lighter patients)
- Consider ticagrelor monotherapy after 1–3 months in high-bleeding-risk patients
- Do not use ticagrelor if fibrinolysis was the reperfusion strategy — use clopidogrel instead
Recent evidence (PMID 39654024 — BMC Pharmacol Toxicol, 2024): Meta-analysis of RCTs confirms ticagrelor reduces major adverse cardiac events compared to clopidogrel in STEMI, with consistent mortality benefit and manageable bleeding risk.
Sources: Fuster and Hurst's The Heart 15th Ed. | Harrison's Principles of Internal Medicine 22nd Ed. | Goodman & Gilman's Pharmacological Basis of Therapeutics | Rosen's Emergency Medicine | Tintinalli's Emergency Medicine
This is a shared conversation. Sign in to Orris to start your own chat.